LEXARIA BIOSCIENCE CORP. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.35 USD | +7.31% |
|
+6.82% | +88.00% |
| Apr. 16 | Lexaria Obtains Ethics Review Board Approval to Start New GLP-1 Study | MT |
| Apr. 16 | Lexaria Bioscience Corp. Receives Ethics Review Board Approval to Begin New GLP-1 Study | CI |
Evolution of the average Target Price on Lexaria Bioscience Corp.
Price target over the last 5 years
History of analyst recommendation changes
7bc1c493.R7F3xY03NqRxilYveD8MfDidf9J_QNfgcbLXeUBLmV8.AtUHifRZd5VExAV-FHM-TQn0CpMzdLqVMIW-NQ440ysYwyGXwQ4P6jX-Hw~c136f4500de302f1dae1d218f58e26be
Analysts' Consensus
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
2.35
USD
Average target price
11
USD
Spread / Average Target
+368.09%
High Price Target
12
USD
Spread / Highest target
+410.64%
Low Price Target
10
USD
Spread / Lowest Target
+325.53%
Consensus detail
Consensus revision (last 18 months)
Analysts covering Lexaria Bioscience Corp.
| Maxim |
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
- Stock Market
- Equities
- LEXX Stock
- Consensus Lexaria Bioscience Corp.
